Orion Portfolio Solutions LLC Sells 851 Shares of Humana Inc. (NYSE:HUM)

Orion Portfolio Solutions LLC cut its position in Humana Inc. (NYSE:HUM) by 15.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,663 shares of the insurance provider’s stock after selling 851 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Humana were worth $1,477,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of HUM. CarsonAllaria Wealth Management Ltd. raised its stake in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after acquiring an additional 39 shares in the last quarter. Creative Financial Designs Inc. ADV increased its position in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares in the last quarter. Atwood & Palmer Inc. purchased a new stake in shares of Humana during the 3rd quarter valued at $29,000. Hantz Financial Services Inc. acquired a new stake in shares of Humana in the 2nd quarter worth $35,000. Finally, Family Firm Inc. purchased a new position in Humana during the 2nd quarter worth $37,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of Humana stock opened at $274.14 on Friday. The firm has a market cap of $33.01 billion, a PE ratio of 24.28, a P/E/G ratio of 2.15 and a beta of 0.53. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $486.00. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $274.13 and a 200 day moving average price of $324.70.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The business had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Sell-side analysts predict that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.885 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.29%. Humana’s dividend payout ratio (DPR) is 31.36%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HUM. Stephens reissued an “equal weight” rating and issued a $250.00 price target on shares of Humana in a report on Wednesday, October 9th. Piper Sandler downgraded shares of Humana from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $392.00 to $274.00 in a research report on Thursday, October 3rd. Wells Fargo & Company decreased their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Jefferies Financial Group lowered shares of Humana from a “buy” rating to a “hold” rating and dropped their price objective for the company from $519.00 to $253.00 in a report on Monday, October 7th. Finally, Barclays raised their target price on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $304.15.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.